Aclara BioSciences has entered into an eTag Access Agreement with GlaxoSmithKline (GSK), under which GSK will gain access to Aclara's proprietary eTag Assay System for use in its biopharmaceutical research and development activities. In addition to leveraging Aclara's state-of-the-art custom assay development services, GSK, a leading, London-based healthcare company, will also utilize eTag assay reagent products and software for multiplexed gene expression profiling studies.

"We are very pleased that GSK has chosen to incorporate Aclara's eTag Assay System into its drug discovery and development programs," said Thomas Klopack, Aclara's chief executive officer. "This agreement will enable GSK to use the eTag Assay System to gain significant insight into biology in a high throughput, targeted fashion, thereby accelerating the advancement of new biopharmaceuticals."